Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year‑on‑year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex‑China business – validating the company’s international commercialization strategy across 60 countries and regions.
China Biosimilar Market Leadership: Henlius’s 16.5% revenue growth outpaces industry average (~10%) driven by innovator‑quality manufacturing and aggressive pricing; trastuzumab (HERCESSI/Zercepac) and serplulimab (PD‑1) franchises defend against domestic competition (Bio‑Thera, Cinda Biologics) through global regulatory credibility (FDA/EMA approvals).
Ex‑China Inflection:Doubling of ex‑China revenue to >RMB 200 million with RMB 93.9 million profit demonstrates sustainable international unit economics – critical for valuation re‑rating from “China‑only biosimilar” to “global biotech platform”; US HERCESSI launch (2024‑2025) and EU Zercepac market share gains drive 2026‑2027 trajectory.
R&D Productivity:RMB 2.5 billion R&D investment (+35.4%) yields 27 INDs – industry‑leading pace for China biotech; pipeline includes HLX15 (daratumumab), HLX13 (ipilimumab), novel ADCs, and bispecific antibodies; Dr. Reddy’s and Sandoz partnerships validate early‑stage asset attractiveness for global licensing.
Partnership‑Driven Growth: 2025 collaborations with Abbott, Eisai, Lotus, Dr. Reddy’s, Sandoz transform Henlius from product‑centric to platform‑centric business model; licensing revenue streams (milestones, royalties) reduce dependency on product sales volatility; estimated RMB500‑800 million annual licensing revenue potential by 2027‑2028.
2026 Strategic Priorities: US HERCESSI market share expansion (target 15‑20% of trastuzumab biosimilar volume); EU Hetronifly (serplulimab) launch completion; HLX15/HLX13 Phase III execution; novel biologics (ADCs, bispecifics) IND acceleration; potential secondary listing (US or EU) to access global capital markets.
Forward‑Looking Statements This brief contains forward‑looking statements regarding revenue growth expectations, partnership performance, and global expansion timelines for Henlius Biotech. Actual results may differ due to competitive pricing pressures, regulatory approval delays in key markets, and manufacturing scale‑up challenges for novel biologics.-Fineline Info & Tech
By Fineline Cube 